STOCK TITAN

Avalo Therapeutics (AVTX) Stock News, Feb-Aug 2022

AVTX NASDAQ

Avalo Therapeutics, Inc. reports developments for a clinical-stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases. Its recurring updates center on abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody evaluated in hidradenitis suppurativa, including LOTUS trial results, safety and efficacy disclosures, and program development plans.

Company news also covers financial results, investor presentations and conferences, equity compensation grants, public financing activity involving common stock and pre-funded warrants, and milestone obligations tied to the AlmataBio acquisition. These updates connect Avalo's clinical pipeline, capital needs, and governance actions to its public-company reporting cycle.

Rhea-AI Summary

Avalo Therapeutics has announced that the first patient has been dosed in the pivotal LADDER trial for their drug AVTX-803, aimed at treating Leukocyte Adhesion Deficiency Type II (LAD II). This Phase 3 trial is randomized, double-blind, and designed to evaluate the drug's efficacy and safety over 16 weeks. AVTX-803 has received multiple designations, including Rare Pediatric Disease and Fast Track. Results are expected in 1H 2023, potentially leading to regulatory approval and a Priority Review Voucher.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
-
Rhea-AI Summary

Avalo Therapeutics has entered into a worldwide exclusive license agreement with Apollo Therapeutics for AVTX-007, its IL-18 monoclonal antibody. Avalo will receive an upfront payment of approximately $15 million, including $5 million upon agreement execution and $10 million for transfer activities. Apollo will also pay up to $74 million in milestone payments and a small royalty on sales. This agreement will enable Avalo to extend its cash runway and concentrate on its lead molecule, AVTX-002, while transferring clinical development responsibilities to Apollo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX) announced a one-for-twelve reverse stock split effective July 7, 2022. This move aims to increase the stock price to meet Nasdaq Capital Market listing requirements. Following the split, shares outstanding will decrease from approximately 112.9 million to around 9.4 million. The reverse split will not affect the ownership percentage of stockholders, except those with fractional shares, who will receive whole shares. The company's stock will begin trading on a split-adjusted basis on July 8, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.97%
Tags
Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX) announced that CEO Garry A. Neil will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 4:00 PM ET in New York. A live webcast will be available on the Company's website, and a replay will last for 90 days. Avalo Therapeutics focuses on precision medicine, aiming to develop targeted therapeutics for immunology and rare genetic diseases. Their clinical candidates are backed by proven mechanisms and established proof-of-concept to enhance success probability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
conferences
-
Rhea-AI Summary

Avalo Therapeutics announced the dosing of the first patient in its Phase 2 PEAK trial, investigating AVTX-002 for non-eosinophilic asthma treatment. This randomized, double-blind, placebo-controlled study involves around 80 participants and focuses on the safety and efficacy of AVTX-002 over 12 weeks. The primary endpoint evaluates asthma-related events in patients. With nearly half of asthma patients affected by non-eosinophilic asthma, this trial could address a significant unmet medical need in asthma treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
-
Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX) will have its CEO, Garry A. Neil, present virtually at the H.C. Wainwright Global Life Sciences Conference from May 23-26, 2022. The pre-recorded presentation will be available on May 24, 2022, at 7:00 AM ET. Investors can access the webcast on the company's website under the 'News/Events' section. Avalo is focused on developing targeted therapeutics for significant unmet clinical needs, particularly in immunology and rare genetic diseases, with a diverse portfolio aimed at delivering meaningful medical impact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.08%
Tags
conferences
Rhea-AI Summary

Avalo Therapeutics (AVTX) announced significant updates including the initiation of Phase 2 clinical trials for AVTX-002 in non-eosinophilic asthma and AVTX-803 for leukocyte adhesion deficiency type II. The company executed a workforce reduction of approximately one third to align with pipeline prioritization, aiming to reduce expenses over time. As of March 31, 2022, Avalo reported cash and cash equivalents of $38 million, a decrease driven primarily by operating expenses. The net loss for Q1 2022 was $22.1 million, reflecting continued investment in pipeline development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.27%
Tags
-
Rhea-AI Summary

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage precision medicine company, announced participation at Oppenheimer's 32nd Annual Healthcare Conference on March 16, 2022, at 1:20 p.m. ET. The event will showcase Avalo's innovative therapies, focusing on unmet clinical needs in immunology and rare genetic diseases. A live webcast will be available on their website. Avalo emphasizes its commitment to developing targeted therapeutics, and the potential impact of its portfolio aimed at enhancing patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
conferences
-
Rhea-AI Summary

Avalo Therapeutics (AVTX) announced key updates, including the promotion of Dr. Garry Neil to CEO and Chris Sullivan to CFO. The company plans to initiate a Phase 2 trial for AVTX-002 targeting moderate to severe Non-eosinophilic Asthma, with topline data expected in Q4 2022. As of December 31, 2021, Avalo reported cash and equivalents of $54.6 million, a $35.7 million increase from 2020, driven by public offerings and debt facilities. However, total operating expenses rose by $8 million, primarily due to R&D costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
Rhea-AI Summary

Avalo Therapeutics has announced a leadership transition with Dr. Garry Neil appointed as Chief Executive Officer, effective February 14, 2022. Chris Sullivan has been promoted to Chief Financial Officer. The previous CEO and CFO, Mike Cola and Schond Greenway, respectively, have stepped down. The Board expressed appreciation for their contributions while highlighting the firm's promising future, particularly with the development of AVTX-002 for inflammatory diseases. Both Neil and Sullivan bring extensive experience to their new roles, aiming to enhance operational success and shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.46%
Tags
management

FAQ

What is the current stock price of Avalo Therapeutics (AVTX)?

Avalo Therapeutics (AVTX) last closed at $6.70.

What is the market cap of Avalo Therapeutics (AVTX)?

The market cap of Avalo Therapeutics (AVTX) is approximately $387.4M.